BGNEBeiGene, Ltd.

Nasdaq beigene.com


$ 148.71 $ -5.40 (-3.5 %)    

Friday, 31-May-2024 15:59:46 EDT
QQQ $ 454.82 $ 0.39 (0.09 %)
DIA $ 398.57 $ 6.05 (1.59 %)
SPY $ 530.36 $ 4.76 (0.91 %)
TLT $ 91.26 $ 0.61 (0.68 %)
GLD $ 225.37 $ 0.08 (0.04 %)
$ 148.85
$ 149.34
$ 0.00 x 0
$ 0.00 x 0
$ 146.83 - $ 153.17
$ 126.97 - $ 229.57
287,022
na
15.57B
$ 0.91
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-08-2024 03-31-2024 10-Q
2 02-26-2024 12-31-2023 10-K
3 11-09-2023 09-30-2023 10-Q
4 08-02-2023 06-30-2023 10-Q
5 05-04-2023 03-31-2023 10-Q
6 02-27-2023 12-31-2022 10-K
7 11-09-2022 09-30-2022 10-Q
8 08-08-2022 06-30-2022 10-Q
9 05-09-2022 03-31-2022 10-Q
10 02-28-2022 12-31-2021 10-K
11 11-04-2021 09-30-2021 10-Q
12 08-05-2021 06-30-2021 10-Q
13 05-06-2021 03-31-2021 10-Q
14 02-25-2021 12-31-2020 10-K
15 11-05-2020 09-30-2020 10-Q
16 08-06-2020 06-30-2020 10-Q
17 05-11-2020 03-31-2020 10-Q
18 03-02-2020 12-31-2019 10-K
19 11-12-2019 09-30-2019 10-Q
20 08-08-2019 06-30-2019 10-Q
21 05-09-2019 03-31-2019 10-Q
22 02-28-2019 12-31-2018 10-K
23 11-08-2018 09-30-2018 10-Q
24 08-09-2018 06-30-2018 10-Q
25 05-09-2018 03-31-2018 10-Q
26 02-28-2018 12-31-2017 10-K
27 11-13-2017 09-30-2017 10-Q
28 08-09-2017 06-30-2017 10-Q
29 05-10-2017 03-31-2017 10-Q
30 03-22-2017 12-31-2016 10-K
31 11-10-2016 09-30-2016 10-Q
32 08-10-2016 06-30-2016 10-Q
33 05-12-2016 03-31-2016 10-Q
34 03-30-2016 12-31-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 lululemon-athletica-was-among-the-worst-performing-stocks-last-week-may-19-may-26-2024-are-these-10-large-cap-stock-losers-in-your-portfolio

10 worst-performing large-cap stocks last week. National Grid, James Hardie, KE Holdings, JD.Com, XP, Nordson, BeiGene, Lululem...

 beigene-says-brukinsa-data-at-american-society-of-clinical-oncology-asco-annual-meeting-in-chicago-underscore-differentiated-clinical-profile-for-treatment-of-cll-and-sll

 The presentations highlight analyses of the efficacy and safety of BRUKINSA compared to other Bruton's tyrosine kinase inh...

 beigene-to-highlight-new-hematology-portfolio-and-pipeline-data-at-eha2024-june-13-16-2024

Study evaluating BRUKINSA® in combination with venetoclax in high-risk, treatment-naïve CLL/SLL patients to be shared as oral p...

 td-cowen-maintains-buy-on-beigene-raises-price-target-to-254

TD Cowen analyst Yaron Werber maintains BeiGene (NASDAQ:BGNE) with a Buy and raises the price target from $236 to $254.

 beigene-q1-2024-gaap-epads-241-beats-289-estimate-sales-751652m-beat-676451m-estimate

BeiGene (NASDAQ:BGNE) reported quarterly losses of $(2.41) per share which beat the analyst consensus estimate of $(2.89) by 16...

 tracking-last-weeks-top-performers-are-these-15-large-cap-stocks-in-your-portfolio-april-21-27-2024

Last week's top performers included Vertiv Holdings, Tesla, Tyler Technologies, and Newmont Corporation.

 td-cowen-maintains-buy-on-beigene-raises-price-target-to-236

TD Cowen analyst Yaron Werber maintains BeiGene (NASDAQ:BGNE) with a Buy and raises the price target from $235 to $236.

 b-of-a-securities-maintains-neutral-on-beigene-lowers-price-target-to-1643

B of A Securities analyst David Li maintains BeiGene (NASDAQ:BGNE) with a Neutral and lowers the price target from $179.3 to...

 bernstein-maintains-market-perform-on-beigene-lowers-price-target-to-161

Bernstein analyst Rebecca Liang maintains BeiGene (NASDAQ:BGNE) with a Market Perform and lowers the price target from $196 ...

 lululemon-issues-weak-outlook-joins-nike-and-other-big-stocks-moving-lower-in-fridays-pre-market-session

U.S. stock futures were higher this morning, with the Dow futures gaining by around 0.1% on Friday.

 fda-approves-beigenes-first-drug-candidate-produced-through-its-immuno-oncology-program-for-esophageal-cancer

FDA approves BeiGene's Tevimbra for esophageal squamous cell carcinoma, offering hope for patients after prior chemotherapy...

 beigene-secures-fda-approval-for-tevimbra-for-treatment-of-advanced-or-metastatic-esophageal-squamous-cell-carcinoma-after-prior-chemotherapy

TEVIMBRA will be available in the U.S. in the second half of 2024. The FDA is also reviewing Biologics License Applications (BL...

 fda-approves-beigenes-tevimbra-as-of-march-13-2024

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761232

 why-clover-health-investments-shares-are-trading-higher-by-11-here-are-other-stocks-moving-in-wednesdays-mid-day-session

Shares of Clover Health Investments, Corp. (NASDAQ: CLOV) rose sharply during Wednesday’s session after the company reported b...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION